1Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, P.R. China.
1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2The Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University ...
1Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
Cancer Res (2025) 85 (8_Supplement_2): LB091.
University of Alabama at Birmingham, Birmingham, AL.
Abstract. Molecular glue degrader (MGD) is an emerging therapeutic strategy offering an exciting alternative to traditional small molecules exploring new target space. These small molecules interact ...
Abstract. TNG462 is a clinical-stage, MTA-cooperative PRMT5 inhibitor currently being evaluated in an ongoing phase I/II clinical trial for solid tumors with MTAP loss. Approximately 10-15% of all ...
Suzhou Genhouse Pharmaceutical Co., Ltd., Suzhou, China.
Affinity Biopharmaceutical Co., Ltd., Shanghai, China.
Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon, Republic of Korea.
BIK Therapeutics Inc., Seongnam, Republic of Korea.
Search for other works by this author on: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback